Treatment with MK-7123 50 mg versus placebo led to significant improvement in FEV1 in patients with COPD , suggesting clinically important antiinflammatory effects with CXCR2 antagonism , although dose-related discontinuations were observed because of ANC decreases with MK-7123 .